ROIV

Roivant Sciences Ltd. ROIV

NasdaqLarge CapHealthcare
InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #2,854 of 2,925

Why it scores 12Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.44M

Quarter to Jun 30

Net income

$-189.84M

Quarter to Jun 30

Free cash flow

$-270.92M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$19.74B total
FMR LLC
$2.87B+3.9%
BlackRock, Inc.
$1.71B+9.0%
MORGAN STANLEY
$1.51B-17.8%
QVT Financial LP
$839.56M-5.7%
VANGUARD CAPITAL MANAGEMENT LLC
$782.94M+7.0%
VANGUARD PORTFOLIO MANAGEMENT LLC
$765.89M+9.1%
GOLDMAN SACHS GROUP INC
$656.71M+67.0%
STATE STREET CORP
$629.80M+9.9%
UBS Group AG
$618.14M-22.8%
FARALLON CAPITAL MANAGEMENT LLC
$506.40M+47.9%
GEODE CAPITAL MANAGEMENT, LLC
$425.54M+14.7%
ADAGE CAPITAL PARTNERS GP, L.L.C.
$366.26M-19.1%
Two Seas Capital LP
$299.94M-9.1%
Assenagon Asset Management S.A.
$295.96M+18.2%
PERCEPTIVE ADVISORS LLC
$286.14M-2.4%
Patient Square Capital LP
$283.86M-1.8%
Invesco Ltd.
$266.53M+17.0%
Darwin Global Management, Ltd.
$234.33M-0.7%
AQR CAPITAL MANAGEMENT LLC
$234.03M+11.5%
VIKING GLOBAL INVESTORS LP
$221.95M-5.7%
Rubric Capital Management LP
$212.34M+20.0%
CITADEL ADVISORS LLC
$197.34M+121.6%
DIMENSIONAL FUND ADVISORS LP
$185.06M-30.0%
PRICE T ROWE ASSOCIATES INC /MD/
$170.47M-31.1%
NORGES BANK
$168.01M--
See all 503 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

Q1 2027
EDGAR

Net Income

Q1 2027
EDGAR

EPS (Diluted)

Q1 2027
EDGAR

ROIC

Q1 2027
EDGAR

Free Cash Flow

Q1 2027
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ROIV

Earnings Per Share

13fpro.ai/company/ROIV

Loading ratio trend…

ROIV key financials by period

Reported revenue, net income and operating margin by fiscal year, from Roivant Sciences Ltd.'s annual filings on SEC EDGAR.

Roivant Sciences Ltd. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2026$8.3M$-299.8M—
FY 2025$29.1M$-172.0M—
FY 2024$32.7M$4.3B—
FY 2023$31.5M$-1.0B—
FY 2022$55.3M$-845.3M—
FY 2021$23.8M$-809.2M—
Source: ROIV filings on SEC EDGAR →

Companies similar to ROIV

Ranked by quality-factor profile and overlapping institutional ownership, from the latest 13F filings and SEC financials.

ROIV insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

Congress trading in ROIV

4 transactions in ROIV reported by 1 member of Congress under the STOCK Act, most recent trade Oct 31, 2025. Reported transactions, not recommendations.

All Congress stock trades →

About Roivant Sciences Ltd. (ROIV): stock profile, AI score and financials

Roivant Sciences Ltd. (ROIV) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ROIV at 12.0/100 on a composite quality score built from its SEC filings, placing it at rank #2,854 of 2,925 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2027), Roivant Sciences Ltd. reports quarterly revenue of $1.4M, net income of $-189.8M, free cash flow of $-270.9M. Top institutional holders of ROIV by reported 13-F value include FMR, BlackRock, MORGAN STANLEY, based on the most recent SEC filings. ROIV trades on the Nasdaq exchange and files with the SEC under CIK 1635088. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ROIV daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Roivant Sciences Ltd. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1635088 →